These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9652512)

  • 41. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?--a meta-analysis.
    Liu T; Xu JY; Xu W; Bai YR; Yan WL; Yang HL
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):350-8. PubMed ID: 21094027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nuclear imaging of bone tumors: FDG-PET.
    Aoki J; Inoue T; Tomiyoshi K; Shinozaki T; Watanabe H; Takagishi K; Endo K
    Semin Musculoskelet Radiol; 2001 Jun; 5(2):183-7. PubMed ID: 11500164
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Skeletal scintigraphy in breast cancer management.
    Bares R
    Q J Nucl Med; 1998 Mar; 42(1):43-8. PubMed ID: 9646644
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Semeiotics of bone tumors in children.
    Fasanelli S
    Eur J Radiol; 1998 May; 27 Suppl 1():S110-5. PubMed ID: 9652510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of 18F-FDG PET/CT with bone scintigraphy for detection of bone metastasis: a meta-analysis.
    Cheng X; Li Y; Xu Z; Bao L; Li D; Wang J
    Acta Radiol; 2011 Sep; 52(7):779-87. PubMed ID: 21712464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.
    Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA
    Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual-time point
    Parghane RV; Basu S
    Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Nuclear medicine of bone].
    Fukunaga M; Otsuka N; Sone T
    Kaku Igaku; 1999 Jan; 36(1):7-14. PubMed ID: 10087760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis.
    Liu NB; Zhu L; Li MH; Sun XR; Hu M; Huo ZW; Xu WG; Yu JM
    Asian Pac J Cancer Prev; 2013; 14(6):3647-52. PubMed ID: 23886160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
    Cheran SK; Herndon JE; Patz EF
    Lung Cancer; 2004 Jun; 44(3):317-25. PubMed ID: 15140545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
    Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
    Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
    Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The value of imaging in the diagnosis and treatment of bone tumors.
    Campanacci M; Mercuri M; Gasbarrini A; Campanacci L
    Eur J Radiol; 1998 May; 27 Suppl 1():S116-22. PubMed ID: 9652511
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
    World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
    Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ
    Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
    Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A
    Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer.
    Lee JW; Lee SM; Lee HS; Kim YH; Bae WK
    Ann Nucl Med; 2012 Oct; 26(8):627-33. PubMed ID: 22729551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Combining CT and scintigraphy: SPECT-CT and PET-CT].
    Vöö S; van Dongen TM; Waterval JJ; Willems P; Mottaghy F; Brans B
    Ned Tijdschr Geneeskd; 2011; 155(36):A2792. PubMed ID: 21914229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.